Error 404 - Not Found

Suggestions

YouTube Calendar Photos Documents Reader Sites Groups

Merck announces third- quarter 2009 financial results - Merck News Item Oct 22, 2009 Company Statements · Presentations · VIOXX ® (rofecoxib) Information . The company is expecting a significant decline in future Given the anticipated fourth quarter close of the merger with . The consolidated 2009 non-GAAP tax rate is estimated to be approximately 21 percent to 24 percent .

Merck Profit Falls as Generic Copies Hurt Zocor Sales (Update6 Jan 30, 2007 Merck & Co.'s fourth - quarter profit plunged 58 percent as competition from Shares Decline . Revenue in the quarter rose 4.8 percent to $6.04 billion. excluding Vioxx charges, increased 21 percent as it spent more

Merck Announces Second- Quarter 2010 Financial Results - FierceBiotech Jul 30, 2010 21 -22, 2010 — Hyderabad, India; Life Sciences Summit 2010 . The gross margin was 59.9 percent for the second quarter of 2010, reflecting a 16.6 . quarter of 2010, an 18 percent decline from the same quarter in 2009. . of the company's Vioxx third-party payor litigation in the United States.

Stock: Merck (MRK) Merck Profit Rises More Than Estimated on Cost Cuts . Merck reported net income of $299 million for the quarter , a decrease of 79% for the .. PEG- Intron has seen growth over the last year in the US and Europe but a slight decline in Japanese sales. Vioxx became one of the most prescribed drugs in history.

Merck Announces Fourth - Quarter and Full-Year 2009 Financial Feb 16, 2010 The gross margin was 51.4 percent for the fourth quarter of 2009 and 67.1 a 13 percent decline from the full year of 2008. .. the resolution of an investigation into whether Merck violated state laws with respect to the sales and marketing of VIOXX . .. Asmanex, 37, 21 , 58, 37, 177, 214

merck | Page 5 - NJ.com October 22, 2009, 8: 21AM . WHITEHOUSE STATION -- Drugmaker Merck & Co. posts a bigger profit in the third quarter due to slightly higher sales and a huge

First came Merck's Vioxx , now we have Pfizer warning doctors that (7/ 21 /09)- Merck & Co. and Schering-Plough Corp. agreed to pay the $5.4 million in .. the drop off in the first quarter of this year may be as large as 30%. This civil settlement ends any investigations into Vioxx advertising .. be required to post publicly the results of nearly all human drug trials.

Merck to report on Schering-Plough integration, new biotech Feb 11, 2010 Earnings Preview: Merck to report 4th - qtr results Analysts may ask about withdrawn arthritis pill Vioxx , as Merck this week agreed World Wrestling posts earnings, revenue decline , hurt by lower Ecolab profit grew 45 percent compared to a year ago, but 1st-quarter outlook misses estimates

Stocks to watch: Kohl's, Medtronic, Novell, more Movers & Shakers Movers & Shakers. May 22, 2001, 6:24 p.m. EDT · Recommend · Post : . Revenue was down 23 percent from the fourth quarter to 22.3 million. . Merck notes the results of the Vioxx Gastrointestinal Research study were released in March 2000, July 21 , 2010, Wednesday's biggest gaining and declining stocks

S&P Picks and Pans: Qualcomm, Wachovia, Fannie, Merck , Lennar Nov 9, 2007 We are reducing our fourth quarter and 2007 EPS estimates, Merck agrees to pay $4.85B to settle majority of the Vioxx heart Although Fannie continues to gain market share, credit deterioration amid declining home prices hurt results. we are lowering our target price to $18 from $21 .